The estimated Net Worth of Kyle Jenne is at least $967 Mille dollars as of 22 September 2020. Kyle Jenne owns over 720 units of Akcea Therapeutics Inc stock worth over $945,058 and over the last 5 years Kyle sold AKCA stock worth over $22,200.
Sign up
Kyle Jenne AKCA stock SEC Form 4 insiders trading
Kyle has made over 2 trades of the Akcea Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Kyle sold 720 units of AKCA stock worth $13,046 on 22 September 2020.
The largest trade Kyle's ever made was selling 779 units of Akcea Therapeutics Inc stock on 23 March 2020 worth over $9,153. On average, Kyle trades about 250 units every 31 days since 2019. As of 22 September 2020 Kyle still owns at least 52,012 units of Akcea Therapeutics Inc stock.
You can see the complete history of Kyle Jenne stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kyle Jenne's mailing address?
Kyle's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.
Insiders trading at Akcea Therapeutics Inc
Over the last 7 years, insiders at Akcea Therapeutics Inc have traded over $384,023 worth of Akcea Therapeutics Inc stock and bought 35,029,381 units worth $610,464,515 . The most active insiders traders include Pharmaceuticals Inc Ionis, Paula Soteropoulos e B Lynne Parshall. On average, Akcea Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $40,228,816. The most recent stock trade was executed by Pharmaceuticals Inc Ionis on 10 October 2020, trading 21,237,715 units of AKCA stock currently worth $385,464,527.
What does Akcea Therapeutics Inc's logo look like?
Complete history of Kyle Jenne stock trades at Ionis Pharmaceuticals Inc e Akcea Therapeutics Inc
Akcea Therapeutics Inc executives and stock owners
Akcea Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Barbara Yanni,
Director -
Amber Salzman,
Director -
Joseph Iii Klein,
Director -
Michael J. Yang,
Director -
Pharmaceuticals Inc Ionis,
10% owner -
Michael F Mac Lean,
Chief Financial Officer -
Jeff Marc Goldberg,
Chief Operating Officer -
Louis O'dea,
Chief Medical Officer -
Paula Soteropoulos,
Chief Executive Officer -
Elaine Hochberg,
Director -
Edward M Fitzgerald,
Director -
Sandford D Smith,
Director -
Richard A Moscicki,
Director -
Sarah Boyce,
President -
Christopher Gabrieli,
Director -
Alex G. Howarth,
Chief Operating Officer -
B Lynne Parshall,
Director -
Kyle Jenne,
Chief Commercial Officer -
Michael Dennis Price,
Chief Financial Officer -
Damien Mc Devitt,
Chief Executive Officer -
Joshua F. Patterson,
General Counsel -
William T. Andrews,
Chief Medical Officer